{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "07073 Obstetric Cholestasis 6.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "OBSTETRIC CHOLESTASIS"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "07073"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "6.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "Midwives Obstetricians"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "12 November 2020"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "11 November 2023"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "RCOG Green \u2013top guideline No 43"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Women's and Children's"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Miss Dutta, Obstetrics Consultant"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2610 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2612 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Maternity and Gynaecology Practice Steering Group"
                    },
                    {
                        "text": "23 October 2020"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Miss Thakur, Clinical Director"
                    },
                    {
                        "text": "23 October 2020"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "27 October 2020"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group)"
                    },
                    {
                        "text": "November 2020"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612Trust Intranet \u2610Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "07073 Obstetric Cholestasis 6.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 13,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With: this must include Pharmacy if the document has any reference to medication"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Miss Rao"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Mr Gangooly"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Mr Partington"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Mr Spencer"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Miss Sharma"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Mr Fiadjoe"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Miss Joshi"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Miss Kausar"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Amanda Dixon"
                    },
                    {
                        "text": "Labour Ward Manager, Lead midwife for Acute Inpatient Services"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Angela Woolfenden"
                    },
                    {
                        "text": "Lead Midwife for Community Services"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Lavina D'Souza"
                    },
                    {
                        "text": "Lead Midwife for Antenatal Clinic"
                    },
                    {
                        "text": "13 October 2020"
                    },
                    {
                        "text": "Claire Fitzgerald"
                    },
                    {
                        "text": "Pharmacy"
                    },
                    {
                        "text": "13 October 2020"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "(Refer to the main body of the text) 04071 Standard Infection Prevention 04072 Hand Hygiene 06036 Guideline for Maternity Record Keeping including Documentation in Handheld Records 06031 Communicating Test results in Maternity by both Hospital and Community"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 11,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Nicola Leslie"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "January 2007"
                    },
                    {
                        "text": "2.1"
                    },
                    {
                        "text": "Nicola Leslie"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "December 2007"
                    },
                    {
                        "text": "2.2"
                    },
                    {
                        "text": "Sarah Moon"
                    },
                    {
                        "text": "Front sheet, equality and diversity; audit and monitoring"
                    },
                    {
                        "text": "April 2010"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Nicky Leslie"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "April 2011"
                    },
                    {
                        "text": "4.0"
                    },
                    {
                        "text": "Anita Rao"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "September 2014"
                    },
                    {
                        "text": "4.1"
                    },
                    {
                        "text": "Madhulika Joshi"
                    },
                    {
                        "text": "clarification to point 7.8"
                    },
                    {
                        "text": "May 2016"
                    },
                    {
                        "text": "5.0"
                    },
                    {
                        "text": "Anita Dutta"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "20 December 2017"
                    },
                    {
                        "text": "5.1"
                    },
                    {
                        "text": "Sameena Kausar"
                    },
                    {
                        "text": "Clarification to points 8.9, 8.12, 8.15 Appendix A"
                    },
                    {
                        "text": "12 September 2019"
                    },
                    {
                        "text": "6.0"
                    },
                    {
                        "text": "Dr Suman Dadhich"
                    },
                    {
                        "text": "Full review: clarification to points 2.0, 4.0, 9.5, 10.0, 14.0,"
                    },
                    {
                        "text": "12 November 2020"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Introduction ................................................................................................................."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Equality Impact Assessment ..................................................................................... 4"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background ................................................................................................................. 4"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Role and Responsibilities within the Trust ............................................................... 4"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Risk Factors ................................................................................................................ 5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Signs and Symptoms of Obstetric Cholestasis ....................................................... 5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Referral Guidance ....................................................................................................... 6"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Initial Assessment ...................................................................................................... 6"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Management of Obstetric Cholestasis ...................................................................... 7 10 Training Requirements ............................................................................................. 10 11 Professional Midwifery Advocates .......................................................................... 10 12 Infection Prevention ................................................................................................. 10 13 Monitoring and Audit ................................................................................................ 11 14 Approval and Implementation.................................................................................. 11"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Flow chart for Diagnosis, treatment and Management of Obstetric Cholstasis ..............................................................................................................................................12"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Preliminary Equality Analysis ................................................................... 13"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This guideline identifies the fetal risks associated with obstetric cholestasis and provides guidance on the different management choices and the options available for its"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "text": "treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Equality impact assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "Mid and South Essex NHS Foundation Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix B)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "In England, obstetric cholestasis (also referred to as intrahepatic cholestasis of pregnancy) affects 0.7% of pregnancies in multi-ethnic populations1 and 1.2\u20131.5% of women of Indian\u2013Asian or Pakistani\u2013Asian origin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "Prevalence is influenced by genetic and environmental factors and varies between populations worldwide. For example, in Chile, 2.4% of all pregnancies are affected, with a 5% prevalence in women of Afro Caribbean and Indian origin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 3.3,
                "text": "Obstetric cholestasis is a multifactorial condition of pregnancy characterised by pruritus in the absence of a skin rash with abnormal liver function tests (LFTs), neither of which has an alternative cause and both of which resolve after birth. Most authorities accept elevations of any of a wide range of LFTs beyond pregnancy-specific limits."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "prefix": 3.4,
                "text": "Investigations to exclude other causes of pruritus and of abnormal LFTs should"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "be performed. The clinical importance of obstetric cholestasis lies in the potential fetal risks, which may include spontaneous preterm birth, iatrogenic preterm birth and fetal death. There can also be maternal morbidity in association with the intense pruritus and consequent sleep deprivation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Roles and responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The Specialist Nurse for Guidelines and Audit is responsible for ensuring clinical policies, guidelines and SOPs, are evidence-based and developed in line with national guidelines and following appropriate consultation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The clinical director is responsible for the implementation of this guideline within the directorate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "The Head of Midwifery, maternity matrons and maternity managers are responsible for ensuring maternity staff are aware of the guideline and implement it."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "The Obstetric Clinical Lead Consultant and Labour Ward Lead Consultant are responsible for ensuring the implementation of this guideline within the clinical setting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "All maternity staff are responsible for ensuring they are familiar with this guideline in relation to their practice and have the appropriate skills to implement this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Risk factors"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Obstetric cholestasis occurs when there is a reduced flow of bile down the bile ducts from the liver. Some of the bile then \u2018leaks' out into the blood stream, in particular, the bile salts. These then circulate in the bloodstream and can cause symptoms, such as pruritus (itching)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "There is evidence that obstetric cholestasis runs in families. There is also a risk of obstetric cholestasis recurring in a subsequent pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "Some doctors believe that pregnancy related hormones affect the way that the liver works and can cause obstetric cholestasis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "In a hospital setting, the current additional risk of stillbirth in obstetric cholestasis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "above that of the general population has not been determined but is likely to be small"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "prefix": 5.5,
                "text": "Women with obstetric cholestasis should be booked in under consultant-led, team based care and give birth in a hospital unit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Signs and Symptoms of Obstetric Cholestasis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "The following list highlights details of the signs and symptoms of cholestasis:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "Itching that generally begins or is most intense on the arms, legs, palms of hands and soles of feet;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "The itching is usually worse at night;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "Some patients scratch so intensely that their skin breaks and bleeds;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "There is difficulty sleeping;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "Tiredness;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "Poor appetite;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "Nausea;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "Feeling unwell;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "Dark urine and pale stools;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "Jaundice of eyes and skin (uncommon)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "Obstetric cholestasis is diagnosed when otherwise unexplained pruritus occurs in"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "pregnancy and abnormal liver function tests (LFTs) and/or raised bile acids occur in the pregnant woman and both resolve after delivery. Pruritus that involves the palms and soles of the feet is particularly suggestive."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Referral guidance"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Patients with the above symptoms should be referred to DAU (Day Assessment Unit) or ANC (Antenatal Clinic), for assessment and blood to be taken. Abnormal liver function tests (LFT s) and bile acids can aid diagnosis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Initial assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Ascertain any relevant family history."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "Inspection of the skin, will confirm whether the itching is related to other skin conditions, such as eczema."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "prefix": 8.3,
                "text": "Investigations to be undertaken as follows:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "Bloods to be taken for FBC; U&E's and LFT's."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "(Refer to the guideline for 'Receiving and acting on test results in maternity by both hospital and community'; register number 06031)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "8.3.1 If the LFT blood results are abnormal; taking into consideration the \u2018cut-off' levels in pregnancy; the following should be initiated:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "For transaminases, gamma-glutamyl transferase and bilirubin, the upper limit of normal throughout pregnancy is 20% lower than the non-pregnant range;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "It is important to check for other causes of abnormal liver function tests;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "A viral screen for hepatitis A, B, C, Epstein Barr and cytomegalovirus should be performed;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "Liver auto-immune screen \u2013 anti-smooth muscle antibody chronic active hepatitis. Anti-mitochrondrial antibody to exclude primary biliary cirrhosis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "Ultrasound examination of liver and gall bladder to exclude gallstones."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "prefix": 8.4,
                "text": "Pre-eclampsia and acute fatty liver of pregnancy are pregnancy specific causes of abnormal LFT's and bile acids."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 1,
                "prefix": 8.5,
                "text": "Take and record blood pressure (temperature and pulse, if on DAU) and complete urinalysis. Undertake an abdominal palpation, measure fundal height, ascertain fetal position and auscultation of fetal heart."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "prefix": 28.0,
                "text": "Obstetric cholestasis rarely occurs prior to 28 weeks gestation; thus if the assessment is on DAU and the pregnancy is more than  weeks gestation, perform a CTG for at least"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "20-30 minutes, longer if necessary making sure that the patient uses the fetal movement"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "indicator. Assess the quality of the trace using the NICE (National Institute for Clinical"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "Excellence) classification for CTG (cardiotocograph) interpretation. In cases of obstetric"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "cholestasis prior to this gestation, an assessment should be made on an individual basis. (Refer to the guideline entitled \u2018Fetal heart rate monitoring in pregnancy and labour;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "register number 04265)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "prefix": 8.7,
                "text": "Care plan depends on place of initial assessment:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "All patients can have blood results reviewed on DAU the following day, if suitable for discharge;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "Patients can remain in DAU (or transfer from ANC) to await blood results and review by the obstetric registrar. Care plans should be documented in patient's healthcare records;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "All patients who are considered to have obstetric cholestasis, or awaiting confirmation of diagnosis, require an ANC appointment and plan of care by the consultant."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "prefix": 8.8,
                "text": "Pregnancy-specific reference ranges for LFTs should be used. Other causes of itching and of liver dysfunction should be excluded."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "prefix": 8.9,
                "text": "Once other causes of hepatic impairment have been excluded; then a diagnosis of obstetric cholestasis can be made."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Management of obstetric cholestasis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix A)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "General measures to relieve symptoms:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "Have frequent cool baths;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "Wear loose cotton clothing;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "Do not get too hot;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "Keep your body uncovered at night."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "prefix": 9.2,
                "text": "Possible treatment \u2013 there is no evidence that any specific treatment improves maternal symptoms or neonatal outcomes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "prefix": 9.3,
                "text": "Topical emollients. This includes Epimax cream, calamine lotion and aqueous cream with menthol. These are all safe to use in pregnancy and clinical experience suggests that some patients may obtain slight temporary relief from pruritus, although there is no trial data to support or refute this."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "prefix": 9.4,
                "text": "Antihistamines, such as Chlorpheniramine, may provide some sedation at night, but do not significantly impact on pruritus."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "prefix": 9.5,
                "text": "Ursodeoxycholic Acid \u2013 this is the most commonly used agent prescribed in the UK for"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "relief of pruritus in obstetric cholestasis. Ursodeoxycholic acid (UDCA) was thought to enhance bile acid clearance across the placenta from the fetus.As the pathophysiology of obstetric cholestasis and the mechanism of fetal demise are uncertain, the possible role of UDCA is unclear. Whilst this drug is not licensed for use in pregnancy it is commonly prescribed in the UK. Women should be consented for \u201coff license\u201d use. The UCDA dosage as per BNF is 8-12 mg/kg/day in 2-3 divided doses."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "prefix": 9.6,
                "text": "Menadiol (drug name for Vitamin K, refer to the British National Formulary for specific notes) -: Patients should be offered a supplement of water-soluble vitamin K, usually 10mg daily, by mouth. Data supporting the use of menadiol is sparse, but if there is frank steatorrhoea or prolongation of the prothrombin time, the clinical case for menadiol is stronger. The use of menadiol is aimed at improving both fetal and maternal levels, therefore reducing postpartum haemorrhage and fetal or neonatal bleeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "prefix": 9.7,
                "text": "The following blood tests are required on a weekly basis:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "Coagulation screen \u2013 only if the LFT's are abnormal or platelets are low( If ALT>100 and Platelets Below < 100);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "Liver Function Tests \u2013 abnormalities in transaminases i.e. serum glutamic-pyruvic transaminase (ALT) and serum glutamic \u2013oxalocetic transaminase (AST), gamma glutamyl transferase (Gamma GT), bilirubin and / or bile salts are considered sufficient enough to diagnose obstetric cholestasis. Bilirubin is infrequently raised, with most patients having increased levels of one or more of the remaining LFT s. Bile salt assessment is not easily available and whilst isolated elevation of bile salts may occur; this is uncommon and normal levels of bile salts do not exclude the diagnosis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "It should be noted that the level of AST/ALT is not related to the severity of ICP (intra-hepatic cholestasis of pregnancy);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "The investigations need the addition of anti-smooth muscle antibody analysis. If present the results will indicate chronic hepatitis;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "Women with persistent pruritus and normal biochemistry should have LFTs repeated every 1\u20132 weeks."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 1,
                "prefix": 9.8,
                "text": "Fetal wellbeing"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "Stillbirth is considered to be a major concern in the management of obstetric cholestasis. The current stillbirth rate for obstetric cholestasis is comparable with the general population; the risk of \u2018untreated' obstetric cholestasis is unclear"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "Research shows that there is an increased incidence of premature birth, but evidence of an increased risk of meconium stained liquor, caesarean section or postpartum haemorrhage is inconclusive"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "Ultrasound scans for fetal growth will be indicated only on clinical grounds; ultrasound is not reliable methods for preventing fetal death in obstetric cholestasis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "Poor outcome cannot currently be predicted by biochemical results and delivery decisions should not be based on results alone"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 1,
                "prefix": 9.9,
                "text": "Plan of Care"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "All patients with suspected obstetric cholestasis should be reviewed by their consultant, who will confirm diagnosis and form a plan of care;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "Once obstetric cholestasis is diagnosed, it is reasonable to measure LFTs weekly until Delivery;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "Care will be shared between the obstetric consultant and if suitable, outpatient care in DAU (Day Assessment Unit). Regular attendance in antenatal clinic will allow for reviews by the obstetric consultant;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "text": "Weekly attendance to DAU for bloods. No routine twice weekly CTG's unless indicated for other fetal issues like SFD/SGA. Obstetric Cholestasis is not an indication for routine serial fetal growth scans. During each visit observations of temperature, pulse, blood pressure and urinalysis will be checked and recorded. An abdominal palpation will be performed alongside fetal heart rate assessment with a sonicaid. The midwife should give the patient the obstetric cholestasis patient leaflet and various internet sites and discuss the importance of monitoring fetal movements and the possible increased risk of stillbirth;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "text": "Blood will be taken for FBC, U's &E's, LFT'S, bile salts. Coagulation screen will be taken if ALT more than100 and platelets below 100, . All care to be recorded in the patient's handheld maternity records;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "The obstetric registrar on call for labour ward will be able to review the client and alter the care plan if the investigations show a change in the severity of the signs and symptoms;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "prefix": 34.0,
                "text": "Menadiol (Vitamin K) 10mg orally to be administered daily from  weeks of gestation only if the clotting is abnormal. Ensure Menadiol is named to ensure that the water soluble version is dispensed and issued by pharmacy;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "prefix": 37.0,
                "text": "Intramuscular steroid injections for gestations less than  weeks to increase surfactant levels to aid fetal lung maturity may be required for a premature delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "prefix": 37.0,
                "text": "Delivery \u2013 there is insufficient evidence to support or refute the practice of induction of labour around  weeks gestation, aimed at reducing late stillbirth. The timing of a delivery involving cholestasis should be decided by the consultant on an individual basis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "prefix": 37.0,
                "text": "Women should be informed of the increased risk of perinatal morbidity from early intervention (after  weeks and 0 days gestation)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "prefix": 9.12,
                "text": "Women should be informed that the case for intervention (after 37 weeks and 0 days gestation) may be stronger in those with more severe biochemical abnormality. (transaminases ALT more than 100 and bile acids more than 40)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "prefix": 9.13,
                "text": "Women should be informed of the increased risk of maternal morbidity from intervention at 37+0 weeks of gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 0,
                "prefix": 9.14,
                "text": "Women should be informed of the inability to predict stillbirth if the pregnancy continues."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 0,
                "prefix": 38.0,
                "text": "Induction of labour and deliver by  to  weeks gestation if ALT is at/ above 100 and bile acids are more than 40mmols or above. If the ALT is below 100, bile acids are below"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 0,
                "text": "Obstetric Cholestasis / 07073 /6.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "prefix": 40.0,
                "text": "40 and/or clotting is normal, normal fetal growth on GROW chart, and patient having good fetal movement perception consider delivery at 39 to  weeks gestation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "prefix": 9.16,
                "text": "Continuous CTG monitoring should be undertaken when in labour."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "prefix": 10.0,
                "text": "Women should be offered follow-up with a healthcare professional with the necessary skills and expertise to provide appropriate counselling and to ensure that LFT's have returned to normal. The blood test should be deferred for at least  days, as LFT's can increase in the first  days after a pregnancy where obstetric cholestasis has occurred."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "prefix": 10.0,
                "text": "If the blood tests remain abnormal after the th day they need to be repeated 6 weeks post delivery. If the blood tests continue to be abnormal then refer to the gastroenterologist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Training requirements"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "All staff should ensure that their knowledge and skills are up-to-date in order to complete their portfolio for appraisal."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "prefix": 10.2,
                "text": "All qualified midwifery staff are fully trained to take specified blood samples for investigations into cholestasis. Some maternity care assistants (MCAs) are also trained to perform maternal venepuncture. Regular updates for venepuncture are available from the Practice Development Midwife. Midwifery students may undertake venepucture once they have the theoretical knowledge and while under the supervision of a midwife or Obstetrician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 1,
                "prefix": 10.3,
                "text": "Guideline Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "text": "10.3.1 As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust's intranet site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Professional midwifery advocates"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "Professional Midwifery Advocates provide a mechanism of support and guidance to women and midwives. Professional Midwifery Advocates are experienced practising midwives who have undertaken further education in order to supervise midwifery services and to advise and support midwives and women in their care choices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "Infection prevention"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "All staff should follow Trust guidelines on infection prevention by ensuring that they wash their hands before and after each procedure and when taking samples of blood for investigation to use the Aseptic Non-Touch Technique (ANTT)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Audit and monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "prefix": 13.1,
                "text": "Audit of compliance with this guideline will be considered on an annual audit basis in accordance with the Clinical Audit Strategy and Policy (register number 08076), the Corporate Clinical Audit and Quality Improvement Project Plan and the Maternity annual audit work plan; to encompass national and local audit and clinical governance identifying key harm themes. The Women's and Children's Clinical Audit Group will identify a lead for the audit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "prefix": 13.2,
                "text": "The findings of the audit will be reported to and approved by the Multi-disciplinary Risk Management Group (MRMG) and an action plan with named leads and timescales will be developed to address any identified deficiencies. Performance against the action plan will be monitored by this group at subsequent meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "prefix": 13.3,
                "text": "The audit report will be reported to the monthly Directorate Governance"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "text": "Meeting (DGM) and significant concerns relating to compliance will be entered on the local Risk Assurance Framework."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "prefix": 13.4,
                "text": "Key findings and learning points from the audit will be submitted to the Patient Safety Group within the integrated learning report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "prefix": 13.5,
                "text": "Key findings and learning points will be disseminated to relevant staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Approval and implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "All policies, procedures and guidelines will be approved locally by the Maternity and Gynaecology Practice Steering Group prior to submission to the Controlled Document team for ratification by the Joint Document Management Group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "prefix": 14.2,
                "text": "It is the Guidelines and Audit Nurse's and author's responsibility to inform the Maternity and Gynaecology Practice Steering Group and appropriate Maternity Services' staff of the approved policy documents when they are uploaded to the Trust's Intranets."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "text": "Royal College of Obstetricians and Gynaecologists (2011) Obstetric Cholestasis. Green top Guidelines Guideline No. 43, April. RCOG: London"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "text": "Obstetric Cholestasis / 07073 /6.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "text": "Obstetric Cholestasis / 07073 /6.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 1,
                "text": "Appendix A: Flow Chart for the Diagnosis, treatment and Management of Obstetric Cholestasis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "Woman presents with pruritus with or without a rash"
            }
        },
        {
            "type": "image",
            "sequence_num": 157,
            "data": {
                "url": "07073 Obstetric Cholestasis 6.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "text": "Initial Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "Bile acids (BA) & Liver function tests (LFT's)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "Exclude dermatological condition, but can be concomitant with ICP"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "Group A  Group B  Group C"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "BA normal  BA normal  BA raised"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "Exclude other causes of hepatic impairment: If pruritus persists repeat BA & LFT  Exclude other causes of hepatic impairment:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "text": "weekly until symptoms resolve  Hepatitis B & C serology, Autoantibody screen"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "Hepatitis A, B & C serology, Autoantibody screen"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "text": "(AMA, SMA). Liver ultrasound."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "text": "(AMA, SMA). Liver ultrasound."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 0,
                "text": "BA  BA  BA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 0,
                "text": "normal  normal  raised  If pruritus persists  If above negative \u2013 diagnose ICP"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 0,
                "text": "Repeat BA & LFT weekly ALT/AST normalises/"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "text": "ALT/AS ALT/AS ALT/AS stabilises, and patients symptoms resolve."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "text": "T  T raised  T raised"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "text": "normal  Commence UDCA 500 mg BD* Manage  Manage  BA normal  ALTBA /ASTnor mraaisl ed  BA & LFT weekly until delivery"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "text": "Continu as  ALT/AST raised"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 0,
                "text": "Continue as above  Manage as Group C"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 0,
                "text": "UDCA may be increased by 250-500 mg per week if there is no improvement in symptoms or biochemistry, to a maximum"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 0,
                "prefix": 300.0,
                "text": "dose of 2g/day in divided doses. Consider introducing rifampicin as an adjunct therapy if bile acids remain > 100 \u00b5mol/L  BA <40 and < 34/40  BA > 40 and > 34/40 150mg BD increasing up tomg BD but only in conjunction with specialist advice, as the drug can worsen liver action in  Continue weekly BA &  Continue weekly BA some women. Some clinicians will consider delivery before 37/40 depending on level of bile acids  LFT and consider  & LFT. Recommend"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 0,
                "text": "induction and delivery  delivery at 37/40 ** UDCA may be increased by 250-500 mg per week if there is no improvement in symptoms or biochemistry, to a maximum dose  by 40 weeks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 0,
                "prefix": 300.0,
                "text": "of 2g/day in divided doses. Consider introducing rifampicin as an adjunct therapy if bile acids remain > 100 \u00b5mol/L 150mg BD  increasing up tomg BD but only in conjunction with specialist advice, as the drug can worsen liver action in some women."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 0,
                "text": "Some clinicians will consider delivery before 37/40 depending on level of bile acids"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 0,
                "text": "Obstetric Cholestasis / 07073 / 6.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 1,
                "text": "Appendix B: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Obstetric cholestasis/07073 (please tick all that apply)"
            }
        },
        {
            "type": "table",
            "sequence_num": 184,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2612 A change to an existing policy"
                    },
                    {
                        "text": "\u2610 A change to the way staff work"
                    },
                    {
                        "text": "\u2610 A new policy"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 185,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Full review: RCOG Green \u2013top guideline No 43. Clarification to points 2.0, 4.0, 9.5, 10.0, 14.0,"
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "3 yearly review"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and staff"
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "Refer to Pages 1 and 2"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 186,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Dr Suman Dadhich"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Specialist Registrar"
                    },
                    {
                        "text": "12 October 2020"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Page  of"
            }
        }
    ]
}